Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Cancer Ther ; 20(12): 2317-2328, 2021 12.
Article in English | MEDLINE | ID: mdl-34583982

ABSTRACT

The protein arginine methyltransferase 5 (PRMT5) methylates a variety of proteins involved in splicing, multiple signal transduction pathways, epigenetic control of gene expression, and mechanisms leading to protein expression required for cellular proliferation. Dysregulation of PRMT5 is associated with clinical features of several cancers, including lymphomas, lung cancer, and breast cancer. Here, we describe the characterization of JNJ-64619178, a novel, selective, and potent PRMT5 inhibitor, currently in clinical trials for patients with advanced solid tumors, non-Hodgkin's lymphoma, and lower-risk myelodysplastic syndrome. JNJ-64619178 demonstrated a prolonged inhibition of PRMT5 and potent antiproliferative activity in subsets of cancer cell lines derived from various histologies, including lung, breast, pancreatic, and hematological malignancies. In primary acute myelogenous leukemia samples, the presence of splicing factor mutations correlated with a higher ex vivo sensitivity to JNJ-64619178. Furthermore, the potent and unique mechanism of inhibition of JNJ-64619178, combined with highly optimized pharmacological properties, led to efficient tumor growth inhibition and regression in several xenograft models in vivo, with once-daily or intermittent oral-dosing schedules. An increase in splicing burden was observed upon JNJ-64619178 treatment. Overall, these observations support the continued clinical evaluation of JNJ-64619178 in patients with aberrant PRMT5 activity-driven tumors.


Subject(s)
Enzyme Inhibitors/therapeutic use , Lung Neoplasms/drug therapy , Protein-Arginine N-Methyltransferases/drug effects , Pyrimidines/therapeutic use , Pyrroles/therapeutic use , Animals , Disease Models, Animal , Enzyme Inhibitors/pharmacology , Humans , Lung Neoplasms/pathology , Mice , Pyrimidines/pharmacology , Pyrroles/pharmacology
2.
Chemistry ; 18(33): 10393-8, 2012 Aug 13.
Article in English | MEDLINE | ID: mdl-22786664

ABSTRACT

A general directed Ru-catalyzed C(sp(3))-H α-alkylation protocol for piperidines (less-reactive substrates than the corresponding five-membered cyclic amines) has been developed. The use of a hindered alcohol (2,4-dimethyl-3-pentanol) as the solvent and catalyst activator, and a catalytic amount of trans-1,2-cyclohexanedicarboxylic acid is necessary to achieve a high conversion to product. This protocol was used to effectively synthesize a number of 2-hexyl- and 2,6-dihexyl piperidines, as well as the alkaloid (±)-solenopsin A. Kinetic studies have revealed that the carboxylic acid additive has a significant effect on catalyst initiation, catalyst longevity, and reverses the reaction selectivity compared with the acid-free reaction (promotes alkylation versus competing alkene reduction).


Subject(s)
1-Propanol/chemistry , Alcohols/chemistry , Amines/chemistry , Carboxylic Acids/chemistry , Piperidines/chemistry , Ruthenium/chemistry , Alkylation , Catalysis , Molecular Structure , Stereoisomerism
3.
Eur J Med Chem ; 48: 57-68, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22182928

ABSTRACT

In 1991, WHO recognized the resurgence of tuberculosis as a global health problem. Although modern chemotherapy is effective against the causative pathogen Mycobacterium tuberculosis, the current drug regimens have failed to eradicate the disease. The success of the pathogen, partially attributed to drug resistance, necessitates the development of novel anti-tuberculosis drugs. Benzo[j]phenanthridine-7,12-diones, tetracyclic derivatives of the natural product benz[g]isoquinoline-5,10-dione, were conveniently synthesized via palladium-catalyzed intramolecular cyclization of N-methanesulfonyl-3-bromo-2-(arylamino)methyl-1,4-naphthoquinones. Here we report on the bioactivity of eight benzo[j]phenanthridine-7,12-dione derivatives as candidate drug molecules against M. tuberculosis and on their cytotoxicity on C3A human hepatocytes. The strongest antimicrobial activity (as detected by growth inhibition of bacteria, using luminometry and BACTEC 460-TB) and lowest cytotoxicity was found for 3-methylbenzo[j]phenanthridine-7,12-dione 5e, which was also effective in targeting intracellular M. tuberculosis (in murine J774 macrophages) and was not genotoxic for C3A hepatocytes.


Subject(s)
Antitubercular Agents/chemical synthesis , Mycobacterium tuberculosis/drug effects , Palladium/chemistry , Phenanthridines/chemical synthesis , Animals , Antitubercular Agents/chemistry , Antitubercular Agents/pharmacology , Cell Line , Cell Survival/drug effects , Comet Assay , Hepatocytes/drug effects , Humans , Inhibitory Concentration 50 , Magnetic Resonance Spectroscopy , Mass Spectrometry , Mice , Microbial Sensitivity Tests , Molecular Structure , Mycobacterium tuberculosis/growth & development , Phenanthridines/chemistry , Phenanthridines/pharmacology , Spectroscopy, Fourier Transform Infrared
4.
Mini Rev Med Chem ; 7(4): 345-69, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17430222

ABSTRACT

Microwave irradiation has been used to enhance organic reactions since the mid 80's, its use within the field of medicinal chemistry is not so widely evident in the literature. The present review highlights the use of microwave chemistry as an important tool for the fast development of structure activity relationship in several programs related to various therapeutic areas.


Subject(s)
Chemistry, Pharmaceutical , Microwaves , Pharmaceutical Preparations/classification , Structure-Activity Relationship
5.
J Med Chem ; 48(6): 2154-66, 2005 Mar 24.
Article in English | MEDLINE | ID: mdl-15771458

ABSTRACT

Clinical doses of available H(1) antihistamines are limited mainly by sedative side effects. However, higher doses are often required to obtain optimal therapeutic activity, especially in dermatology. We report the synthesis of three norpiperidine imidazoazepines representative of a new class of selective and nonsedating H(1) antihistamines. The compounds were at least as potent as cetirizine and loratadine as measured by H(1) receptor binding affinity, by protection against compound 48/80- and histamine-induced lethality in rats and guinea pigs, respectively, and by skin reaction tests in rats, guinea pigs, and dogs. The compounds, in particular 3a, were less prone than the reference compounds to penetrate the brain and to occupy central H(1) receptors, suggesting absence of sedative side effects. In vitro and in vivo cardiovascular safety tests showed that 3a had no intrinsic potential to prolong ventricular repolarization or induce cardiac arrhythmias. Compound 3a has been selected for further clinical development, mainly for application in dermatology.


Subject(s)
Benzazepines/chemical synthesis , Dermatologic Agents/chemical synthesis , Histamine H1 Antagonists, Non-Sedating/chemical synthesis , Imidazoles/chemical synthesis , Piperidines/chemical synthesis , Spiro Compounds/chemical synthesis , Anaphylaxis/chemically induced , Anaphylaxis/drug therapy , Animals , Arrhythmias, Cardiac/chemically induced , Benzazepines/pharmacology , Benzazepines/toxicity , Blood-Brain Barrier/metabolism , CHO Cells , Cricetinae , Cricetulus , Dermatitis/drug therapy , Dermatitis/immunology , Dermatologic Agents/pharmacology , Dermatologic Agents/toxicity , Dogs , Drug Stability , Female , Guinea Pigs , Histamine H1 Antagonists, Non-Sedating/pharmacology , Histamine H1 Antagonists, Non-Sedating/toxicity , Hydrogen-Ion Concentration , Imidazoles/pharmacology , Imidazoles/toxicity , In Vitro Techniques , Male , Passive Cutaneous Anaphylaxis/drug effects , Piperidines/pharmacology , Piperidines/toxicity , Radioligand Assay , Rats , Rats, Wistar , Solubility , Spiro Compounds/pharmacology , Spiro Compounds/toxicity , Structure-Activity Relationship , Ventricular Function/drug effects
6.
Bioorg Med Chem Lett ; 12(4): 653-8, 2002 Feb 25.
Article in English | MEDLINE | ID: mdl-11844693

ABSTRACT

This communication describes the synthesis and in vitro PDE4 inhibitory activity of a novel series of imidazol-2-one and 2-cyanoiminoimidazole derivatives. The compounds described were also tested in in vivo models to evaluate their anti-inflammatory activity after topical administration as well as their gastro-intestinal side effects. Several compounds proved to be potent PDE4 inhibitors and some 2-cyanoiminoimidazoles showed less pronounced gastro-intestinal side effects than reference compounds but maintained anti-inflammatory activity after topical administration.


Subject(s)
3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors , Anti-Inflammatory Agents/chemical synthesis , Imidazoles/pharmacology , Administration, Topical , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/pharmacology , Cyclic Nucleotide Phosphodiesterases, Type 4 , Disease Models, Animal , Dose-Response Relationship, Drug , Ear Diseases/drug therapy , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Humans , Imidazoles/administration & dosage , Imidazoles/chemical synthesis , Inflammation/drug therapy , Inhibitory Concentration 50 , Rats , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...